Zealand Pharma reports positive phase 1 results for ZP9830

COPENHAGEN - Zealand Pharma A/S (NASDAQ:ZEAL) revealed favorable initial outcomes from the dose progression segment of a Phase 1 trial evaluating ZP9830, an ion channel blocker in development for autoimmune conditions. The trial included 32 healthy individuals in a randomized, double-blind, placebo-controlled design to assess the safety, tolerability, and pharmacokinetics of various doses of ZP9830.

The treatment spanned four weeks, with safety monitoring extending through day 41 post-treatment. Multiple doses of ZP9830 were well-received, with no serious or severe adverse events reported. All observed treatment-related adverse events in participants receiving ZP9830 were non-serious and mild. No dose-limiting safety concerns were identified.

Company officials reported no clinically significant safety findings in vital signs, electrocardiogram readings, physical examinations, or safety laboratory values. Zealand Pharma's Chief Medical Officer, David Kendall, mentioned that ZP9830 was well-tolerated and no dose-limiting safety findings were observed in this phase of the trial.

The company has launched a Phase 1b trial with efficacy endpoints to investigate ZP9830's potential in individuals with plaque psoriasis. Zealand Pharma intends to commence a Phase 2 trial for another autoimmune disease in the first half of 2027. ZP9830 functions by inhibiting Kv1.3, a potassium ion channel that is overexpressed on effector memory T cells, which contribute to autoimmunity and chronic inflammation by releasing pro-inflammatory cytokines.

The trial encompassed single and multiple dose portions, with single dose results announced earlier this year. The trial is also still assessing further single doses of ZP9830. Zealand Pharma, a biotech firm centered on metabolic health, is headquartered in Copenhagen, Denmark. This report was AI-generated and reviewed by a human editor.